Home › Glaucoma › NCT05206877

Topical Insulin for Glaucoma

Topical Insulin for Glaucoma and Optic Neuropathies

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Capable to provide informed consent
* Diagnosis of optic neuropathy either glaucoma or NAION or optic disc drusen.
* Only one eye per patient will be selected as the study eye - if both eyes meet the inclusion criteria, the eye with the worse acuity and /or visual field will be selected. The contralateral eye will be left untouched.

Exclusion Criteria:

* Pregnant or breastfeeding woman
* Presence of any ocular pathologies other than glaucoma that contributes to the severe vision loss (retinopathy / maculopathy, severe uveitis, keratopathy, etc.)
* Diagnosis of glucose intolerance, type 1 or 2 diabetes mellitus
* Inability to perform reliable visual field
* Unable to provide informed consent
* Unable to complete the tests and follow-ups required by the study

About the study

The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).

What is being tested

• Insulin, 4 units (drug)
• Insulin, 20 units (drug)
• insulin, 4 units twice daily (drug)
• insulin, 20 units twice daily (drug)
• insulin, 4 units three times daily (drug)
• insulin, 20 units three times daily (drug)

Sponsor: Stanford University · Participants: 52 · Started: Apr 1, 2022

Contact the study team

• Mariana Nunez, MD · Phone: 650-497-7846

Official record on ClinicalTrials.gov — NCT05206877

Locations in the U.S.

Conditions

• Glaucoma

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.